Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C11H13N2O8.Mg.H |
| Molecular Weight | 326.5425 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H+].[Mg++].CC(=O)N[C@@H](CC([O-])=O)C(=O)N[C@@H](CCC([O-])=O)C([O-])=O
InChI
InChIKey=BQAXDBLSAIPBND-LEUCUCNGSA-L
InChI=1S/C11H16N2O8.Mg/c1-5(14)12-7(4-9(17)18)10(19)13-6(11(20)21)2-3-8(15)16;/h6-7H,2-4H2,1H3,(H,12,14)(H,13,19)(H,15,16)(H,17,18)(H,20,21);/q;+2/p-2/t6-,7-;/m0./s1
| Molecular Formula | C11H14N2O8 |
| Molecular Weight | 302.2375 |
| Charge | -2 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | Mg |
| Molecular Weight | 24.305 |
| Charge | 2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Using proton magnetic resonance imaging and spectroscopy to understand brain "activation". | 2007-08 |
|
| Modulation of GABAergic inhibition in the rat superior colliculus by a presynaptic group II metabotropic glutamate receptor. | 2006-12-01 |
|
| Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain - relation to brain concentration. | 2006-12 |
|
| Ketamine and N-acetylaspartylglutamate peptidase inhibitor exert analgesia in bone cancer pain. | 2006-09 |
|
| Regulation of N-acetylaspartate and N-acetylaspartylglutamate biosynthesis by protein kinase activators. | 2006-09 |
|
| Metabolic analysis of mouse brains that have compromised iron storage. | 2006-09 |
|
| [Alteration of the antinociceptive systems in chronic daily headaches]. | 2006-08-31 |
|
| Identifying the affected hemisphere by (1)H-MR spectroscopy in patients with temporal lobe epilepsy and no pathological findings in high resolution MRI. | 2006-05 |
|
| NAAG peptidase inhibitor increases dialysate NAAG and reduces glutamate, aspartate and GABA levels in the dorsal hippocampus following fluid percussion injury in the rat. | 2006-05 |
|
| NAAG peptidase as a therapeutic target: Potential for regulating the link between glucose metabolism and cognition. | 2006-04 |
|
| ProFit: two-dimensional prior-knowledge fitting of J-resolved spectra. | 2006-04 |
|
| Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. | 2006-03-22 |
|
| Neurotransmitters of the suprachiasmatic nuclei. | 2006-02-16 |
|
| Differential negative coupling of type 3 metabotropic glutamate receptor to cyclic GMP levels in neurons and astrocytes. | 2006-02 |
|
| Metabolite changes in early relapsing-remitting multiple sclerosis. A two year follow-up study. | 2006-02 |
|
| N-acetylaspartylglutamate (NAAG) in Pelizaeus-Merzbacher disease. | 2006 |
|
| N-acetylaspartylglutamate (NAAG) in spinal cord injury and disease. | 2006 |
|
| Synthesis of N-acetylaspartyl-glutamate (NAAG) and N-acetylaspartate (NAA) in axons and glia of the crayfish medial giant nerve fiber. | 2006 |
|
| Functions of N-acetylaspartate and N-acetylaspartylglutamate in brain: evidence of a role in maintenance of higher brain integrative activities of information processing and cognition. | 2006 |
|
| Expression of N-acetylaspartate and N-acetylaspartylglutamate in the nervous system. | 2006 |
|
| A brief overview of N-acetylaspartate and N-acetylaspartylglutamate. | 2006 |
|
| NAAG peptidase inhibitors and their potential for diagnosis and therapy. | 2005-12 |
|
| Optimized diffusion-weighted spectroscopy for measuring brain glutamate apparent diffusion coefficient on a whole-body MR system. | 2005-12 |
|
| Neuroprotective effect of N-acetyl-aspartyl-glutamate in combination with mild hypothermia in the endothelin-1 rat model of focal cerebral ischaemia. | 2005-12 |
|
| Simultaneous high performance liquid chromatographic separation of purines, pyrimidines, N-acetylated amino acids, and dicarboxylic acids for the chemical diagnosis of inborn errors of metabolism. | 2005-11 |
|
| Neonatal administration of N-acetyl-L-aspartyl-L-glutamate induces early neurodegeneration in hippocampus and alters behaviour in young adult rats. | 2005-10-15 |
|
| Mice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and ischemic brain injury. | 2005-10 |
|
| Quantitative proton MRS of Pelizaeus-Merzbacher disease: evidence of dys- and hypomyelination. | 2005-09-13 |
|
| Central N-acetyl aspartylglutamate deficit: a possible pathogenesis of schizophrenia. | 2005-09 |
|
| The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia. | 2005-09 |
|
| The metabotropic glutamate receptor mGluR3 is critically required for hippocampal long-term depression and modulates long-term potentiation in the dentate gyrus of freely moving rats. | 2005-09 |
|
| Glycyl-L-glutamine disposition in rat choroid plexus epithelial cells in primary culture: role of PEPT2. | 2005-08 |
|
| Strategies to increase central N-acetyl aspartylglutamate: a potential treatment for schizophrenia and bipolar disorders. | 2005-07-15 |
|
| Effect of N-acetylaspartylglutamate (NAAG) on non-quantal and spontaneous quantal release of acetylcholine at the neuromuscular synapse of rat. | 2005-07 |
|
| Metabolic characterization of distinct neuroanatomical regions in rats by magic angle spinning 1H nuclear magnetic resonance spectroscopy. | 2005-05 |
|
| Regulation of glutamate carboxypeptidase II hydrolysis of N-acetylaspartylglutamate (NAAG) in crayfish nervous tissue is mediated by glial glutamate and acetylcholine receptors. | 2005-05 |
|
| Stimulation of microglial metabotropic glutamate receptor mGlu2 triggers tumor necrosis factor alpha-induced neurotoxicity in concert with microglial-derived Fas ligand. | 2005-03-16 |
|
| Chronic phencyclidine administration induces schizophrenia-like changes in N-acetylaspartate and N-acetylaspartylglutamate in rat brain. | 2005-03-01 |
|
| In vitro 1H NMR spectroscopy shows an increase in N-acetylaspartylglutamate and glutamine content in the hippocampus of amygdaloid-kindled rats. | 2005-03 |
|
| High-field localized 1H NMR spectroscopy in the anesthetized and in the awake monkey. | 2004-12 |
|
| Serotonin1B receptors: from protein to physiological function and behavior. | 2004-10 |
|
| Quantitative 1H-MRS of healthy human cortex, hippocampus, and thalamus: metabolite concentrations, quantification precision, and reproducibility. | 2004-09 |
|
| Aspartoacylase deficiency does not affect N-acetylaspartylglutamate level or glutamate carboxypeptidase II activity in the knockout mouse brain. | 2004-08-06 |
|
| Biosynthesis of NAAG by an enzyme-mediated process in rat central nervous system neurons and glia. | 2004-08 |
|
| Antinociceptive effects of N-acetylaspartylglutamate (NAAG) peptidase inhibitors ZJ-11, ZJ-17 and ZJ-43 in the rat formalin test and in the rat neuropathic pain model. | 2004-07 |
|
| Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. | 2004-06 |
|
| Severe hypomyelination associated with increased levels of N-acetylaspartylglutamate in CSF. | 2004-05-11 |
|
| NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. | 2004-05 |
|
| The cloning and characterization of a second brain enzyme with NAAG peptidase activity. | 2004-05 |
|
| Protection against glucose-induced neuronal death by NAAG and GCP II inhibition is regulated by mGluR3. | 2004-04 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:51:48 GMT 2025
by
admin
on
Mon Mar 31 22:51:48 GMT 2025
|
| Record UNII |
08Y675ZOIT
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
133585-87-2
Created by
admin on Mon Mar 31 22:51:48 GMT 2025 , Edited by admin on Mon Mar 31 22:51:48 GMT 2025
|
NON-SPECIFIC STOICHIOMETRY | |||
|
113701-65-8
Created by
admin on Mon Mar 31 22:51:48 GMT 2025 , Edited by admin on Mon Mar 31 22:51:48 GMT 2025
|
PRIMARY | |||
|
100000086459
Created by
admin on Mon Mar 31 22:51:48 GMT 2025 , Edited by admin on Mon Mar 31 22:51:48 GMT 2025
|
PRIMARY | |||
|
DTXSID60921166
Created by
admin on Mon Mar 31 22:51:48 GMT 2025 , Edited by admin on Mon Mar 31 22:51:48 GMT 2025
|
PRIMARY | |||
|
08Y675ZOIT
Created by
admin on Mon Mar 31 22:51:48 GMT 2025 , Edited by admin on Mon Mar 31 22:51:48 GMT 2025
|
PRIMARY | |||
|
188802
Created by
admin on Mon Mar 31 22:51:48 GMT 2025 , Edited by admin on Mon Mar 31 22:51:48 GMT 2025
|
PRIMARY | |||
|
SUB02806MIG
Created by
admin on Mon Mar 31 22:51:48 GMT 2025 , Edited by admin on Mon Mar 31 22:51:48 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |